Beihai Gofar Chuanshan Biological Co., Ltd. (BEIHAI GOFAR CHUANSHAN BIOLOGIC) Aktie

Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, engages in the distribution of pharmaceutical products in China. It operates through Pharmaceutical Distribution [Industry]; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails various medicines and medical devices through directly operated and franchised chain drugstores. It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; weichangning granules under the Guofa brand; ethanol disinfectant; honeysuckle mixture; feier syrup; medicinal wine for traumatic injury under the Hippocampus brand; and sea snake medicinal wine. In addition, the company offers forensic DNA testing equipment, reagents, and consumables; and technical services, including DNA testing services. Further, it engages in culture and arts activities. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in June 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was incorporated in 1993 and is headquartered in Beihai, China.